109 related articles for article (PubMed ID: 24382084)
1. Targeted therapy with eculizumab for inherited CD59 deficiency.
Höchsmann B; Dohna-Schwake C; Kyrieleis HA; Pannicke U; Schrezenmeier H
N Engl J Med; 2014 Jan; 370(1):90-2. PubMed ID: 24382084
[No Abstract] [Full Text] [Related]
2. Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation.
Mevorach D; Reiner I; Grau A; Ilan U; Berkun Y; Ta-Shma A; Elpeleg O; Shorer Z; Edvardson S; Tabib A
Ann Neurol; 2016 Nov; 80(5):708-717. PubMed ID: 27568864
[TBL] [Abstract][Full Text] [Related]
3. Hemolytic anemia after eculizumab in paroxysmal nocturnal hemoglobinuria.
Berzuini A; Montanelli F; Prati D
N Engl J Med; 2010 Sep; 363(10):993-4. PubMed ID: 20818912
[No Abstract] [Full Text] [Related]
4. Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab.
Risitano AM; Notaro R; Luzzatto L; Hill A; Kelly R; Hillmen P
N Engl J Med; 2010 Dec; 363(23):2270-2. PubMed ID: 21121856
[No Abstract] [Full Text] [Related]
5. Extravascular hemolytic attack after eculizumab therapy for paroxysmal nocturnal hemoglobinuria.
Tomita A; Shirasugi Y; Ito T; Tsurumi H; Naoe T
Ann Hematol; 2012 Jul; 91(7):1139-41. PubMed ID: 22080148
[No Abstract] [Full Text] [Related]
6. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
[TBL] [Abstract][Full Text] [Related]
7. Successful use of eculizumab in a pediatric patient treated for paroxysmal nocturnal hemoglobinuria.
Bauters T; Bordon V; Robays H; Benoit Y; Dhooge C
J Pediatr Hematol Oncol; 2012 Nov; 34(8):e346-8. PubMed ID: 22767128
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of maize silk in acute hemolytic anemia accompanied with hemoglobinuria. Report of 30 cases.
Chinas Med; 1968 Jul; 7():416-8. PubMed ID: 5700143
[No Abstract] [Full Text] [Related]
9. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.
Röth A; Dührsen U
Eur J Haematol; 2011 Dec; 87(6):473-9. PubMed ID: 21883481
[TBL] [Abstract][Full Text] [Related]
10. [Progress in the management of paroxysmal nocturnal hemoglobinuria by eculizumab].
Nakakuma H
Rinsho Ketsueki; 2011 Aug; 52(8):633-44. PubMed ID: 21897069
[No Abstract] [Full Text] [Related]
11. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation.
Weitz IC; Razavi P; Rochanda L; Zwicker J; Furie B; Manly D; Mackman N; Green R; Liebman HA
Thromb Res; 2012 Sep; 130(3):361-8. PubMed ID: 22542362
[TBL] [Abstract][Full Text] [Related]
12. CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy.
Nevo Y; Ben-Zeev B; Tabib A; Straussberg R; Anikster Y; Shorer Z; Fattal-Valevski A; Ta-Shma A; Aharoni S; Rabie M; Zenvirt S; Goldshmidt H; Fellig Y; Shaag A; Mevorach D; Elpeleg O
Blood; 2013 Jan; 121(1):129-35. PubMed ID: 23149847
[TBL] [Abstract][Full Text] [Related]
13. CD59 deficiency presenting as polyneuropathy and Moyamoya syndrome with endothelial abnormalities of small brain vessels.
Klemann C; Kirschner J; Ammann S; Urbach H; Moske-Eick O; Zieger B; Lorenz MR; Schwarz K; Doostkam S; Ehl S; Korinthenberg R
Eur J Paediatr Neurol; 2018 Sep; 22(5):870-877. PubMed ID: 29843966
[TBL] [Abstract][Full Text] [Related]
14. CD55 and CD59 deficiency in transplant patient populations: possible association with paroxysmal nocturnal hemoglobinuria-like symptoms in Campath-treated patients.
Ruiz P; Weppler D; Tryphonopoulos P; Nishida S; Moon J; Kato T; Selvaggi G; Levi D; Madariaga J; DelaGarza J; Tuteja S; Garcia M; Tzakis A
Transplant Proc; 2006; 38(6):1750-2. PubMed ID: 16908271
[TBL] [Abstract][Full Text] [Related]
15. A closer look at paroxysmal nocturnal hemoglobinuria.
Rachidi S; Musallam KM; Taher AT
Eur J Intern Med; 2010 Aug; 21(4):260-7. PubMed ID: 20603032
[TBL] [Abstract][Full Text] [Related]
16. Drugs that inhibit complement.
Schrezenmeier H; Höchsmann B
Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
[TBL] [Abstract][Full Text] [Related]
17. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of staphylococcal superantigen-like protein 7 for complement-mediated hemolysis.
Li Y; Clow F; Fraser JD; Lin F
J Mol Med (Berl); 2018 Sep; 96(9):965-974. PubMed ID: 30066197
[TBL] [Abstract][Full Text] [Related]
19. Failure of eculizumab to correct paroxysmal cold hemoglobinuria.
Gregory GP; Opat S; Quach H; Shortt J; Tran H
Ann Hematol; 2011 Aug; 90(8):989-90. PubMed ID: 21110191
[No Abstract] [Full Text] [Related]
20. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
